{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T15:48:00Z","timestamp":1765295280798,"version":"build-2065373602"},"reference-count":120,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000266","name":"Engineering and Physical Sciences Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000266","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007123","name":"Stanley Medical Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007123","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brain, Behavior, and Immunity"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.bbi.2022.03.016","type":"journal-article","created":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T03:26:23Z","timestamp":1649042783000},"page":"37-49","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Peripheral lymphocyte signaling pathway deficiencies predict treatment response in first-onset drug-na\u00efve schizophrenia"],"prefix":"10.1016","volume":"103","author":[{"given":"Santiago G.","family":"Lago","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jakub","family":"Tomasik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geertje F.","family":"van Rees","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nitin","family":"Rustogi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"V\u00e1zquez-Bourgon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergi","family":"Papiol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Suarez-Pinilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benedicto","family":"Crespo-Facorro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabine","family":"Bahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbi.2022.03.016_b0005","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nrd2217","article-title":"How can drug discovery for psychiatric disorders be improved?","volume":"6","author":"Agid","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bbi.2022.03.016_b0010","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/nbt.2594","article-title":"viSNE enables visualization of high dimensional single-cell data and reveals phenotypic heterogeneity of leukemia","volume":"31","author":"Amir","year":"2013","journal-title":"Nat. Biotechnol."},{"issue":"S7","key":"10.1016\/j.bbi.2022.03.016_b0015","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1192\/S0007125000291496","article-title":"The Scale for the Assessment of Negative Symptoms (SANS): Conceptual and Theoretical Foundations","volume":"155","author":"Andreasen","year":"1989","journal-title":"Br. J. Psychiatry."},{"key":"10.1016\/j.bbi.2022.03.016_b0020","unstructured":"American Psychiatric Association [APA], The Diagnostic and Statistical Manual of Mental Disorders, fourth edition, text revision (DSM-IV-TR) (2000)."},{"issue":"4","key":"10.1016\/j.bbi.2022.03.016_b0025","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/ajmg.b.30291","article-title":"Association of AKT1 haplotype with the risk of schizophrenia in Iranian population","volume":"141B","author":"Bajestan","year":"2006","journal-title":"Am. J. Med. Genet. B. Neuropsychiatr. Genet."},{"issue":"1","key":"10.1016\/j.bbi.2022.03.016_b0030","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1503\/jpn.110011","article-title":"A role for Akt and glycogen synthase kinase-3 as integrators of dopamine and serotonin neurotransmission in mental health","volume":"37","author":"Beaulieu","year":"2012","journal-title":"J. Psychiatry Neurosci."},{"key":"10.1016\/j.bbi.2022.03.016_b0035","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.pharmthera.2014.11.016","article-title":"Glycogen synthase kinase-3 (GSK3): Regulation, actions, and diseases","volume":"148","author":"Beurel","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bbi.2022.03.016_b0040","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1073\/pnas.1013535108","article-title":"DRD2\/AKT1 interaction on D2 c-AMP independent signaling, attentional processing, and response to olanzapine treatment in schizophrenia","volume":"108","author":"Blasi","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbi.2022.03.016_b0045","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/nature09915","article-title":"Modelling schizophrenia using human induced pluripotent stem cells","volume":"473","author":"Brennand","year":"2011","journal-title":"Nature."},{"key":"10.1016\/j.bbi.2022.03.016_b0050","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00297-20","article-title":"Interferon-Induced Protein 44 and Interferon-Induced Protein 44-Like Restrict Replication of Respiratory Syncytial Virus","volume":"94","author":"Busse","year":"2020","journal-title":"J. Virol."},{"key":"10.1016\/j.bbi.2022.03.016_b0055","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1038\/mp.2012.121","article-title":"Another view of the history of antipsychotic drug discovery and development","volume":"17","author":"Carpenter","year":"2012","journal-title":"Mol. Psychiatry."},{"key":"10.1016\/j.bbi.2022.03.016_b0060","doi-asserted-by":"crossref","DOI":"10.1186\/s13742-015-0047-8","article-title":"Second-generation PLINK: Rising to the challenge of larger and richer datasets","volume":"4","author":"Chang","year":"2015","journal-title":"Gigascience."},{"key":"10.1016\/j.bbi.2022.03.016_b0065","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1128\/MCB.01792-08","article-title":"Leptin deficiency and beta-cell dysfunction underlie type 2 diabetes in compound Akt knockout mice","volume":"29","author":"Chen","year":"2009","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.bbi.2022.03.016_b0070","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1001\/jamapsychiatry.2014.1314","article-title":"Cardiometabolic Risk in Patients With First-Episode Schizophrenia Spectrum Disorders","volume":"71","author":"Correll","year":"2014","journal-title":"JAMA Psychiatry."},{"key":"10.1016\/j.bbi.2022.03.016_b0075","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.pnpbp.2013.02.009","article-title":"Prediction of acute clinical response following a first episode of non affective psychosis: Results of a cohort of 375 patients from the Spanish PAFIP study","volume":"44","author":"Crespo-Facorro","year":"2013","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry."},{"key":"10.1016\/j.bbi.2022.03.016_b0080","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41537-019-0075-y","article-title":"Altered gene expression in antipsychotic-induced weight gain","volume":"5","author":"Crespo-Facorro","year":"2019","journal-title":"npj Schizophr."},{"key":"10.1016\/j.bbi.2022.03.016_b0085","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1128\/MCB.24.1.258-269.2004","article-title":"Essential Role of STAT3 in Body Weight and Glucose Homeostasis","volume":"24","author":"Cui","year":"2004","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.bbi.2022.03.016_b0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/597395","article-title":"Reelin in the years: controlling neuronal migration and maturation in the mammalian brain","volume":"2014","author":"D\u2019Arcangelo","year":"2014","journal-title":"Adv. Neurosci."},{"key":"10.1016\/j.bbi.2022.03.016_b0095","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/nrn2297","article-title":"From inflammation to sickness and depression: when the immune system subjugates the brain","volume":"9","author":"Dantzer","year":"2008","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.bbi.2022.03.016_b0100","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1158\/2326-6066.CIR-19-0493","article-title":"CD40 enhances type I interferon responses downstream of CD47 blockade, bridging innate and adaptive immunity","volume":"8","author":"de Silva","year":"2020","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.bbi.2022.03.016_b0105","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/nmeth.2307","article-title":"Improved whole-chromosome phasing for disease and population genetic studies","volume":"10","author":"Delaneau","year":"2013","journal-title":"Nat. Methods."},{"key":"10.1016\/j.bbi.2022.03.016_b0110","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/sji.12449","article-title":"Autoantibody Specificities and Type I Interferon Pathway Activation in Idiopathic Inflammatory Myopathies","volume":"84","author":"Ekholm","year":"2016","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.bbi.2022.03.016_b0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fnmol.2012.00033","article-title":"AKT\/GSK3 signaling pathway and schizophrenia","volume":"5","author":"Emamian","year":"2012","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.bbi.2022.03.016_b0120","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3389\/fnmol.2012.00033","article-title":"AKT\/GSK3 signaling pathway and schizophrenia","volume":"5","author":"Emamian","year":"2012","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.bbi.2022.03.016_b0125","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/ng1296","article-title":"Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia","volume":"36","author":"Emamian","year":"2004","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bbi.2022.03.016_b0130","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/j.neuropharm.2011.01.011","article-title":"The viral theory of schizophrenia revisited: Abnormal placental gene expression and structural changes with lack of evidence for H1N1 viral presence in placentae of infected mice or brains of exposed offspring","volume":"62","author":"Fatemi","year":"2012","journal-title":"Neuropharmacology."},{"key":"10.1016\/j.bbi.2022.03.016_b0135","first-page":"1","article-title":"Elevated peripheral cytokines characterize a subgroup of people with schizophrenia displaying poor verbal fluency and reduced Broca\u2019s area volume","volume":"21","author":"Fillman","year":"2015","journal-title":"Mol. Psychiatry."},{"key":"10.1016\/j.bbi.2022.03.016_b0140","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1074\/jbc.274.2.571","article-title":"Activation of a CrkL-Stat5 signaling complex by type I interferons","volume":"274","author":"Fish","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbi.2022.03.016_b0145","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nature12929","article-title":"De novo mutations in schizophrenia implicate synaptic networks","volume":"506","author":"Fromer","year":"2014","journal-title":"Nature."},{"key":"10.1016\/j.bbi.2022.03.016_b0150","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1176\/appi.ajp.2009.09060802","article-title":"International consensus study of antipsychotic dosing","volume":"167","author":"Gardner","year":"2010","journal-title":"Am. J. Psychiatry."},{"key":"10.1016\/j.bbi.2022.03.016_b0155","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.pnpbp.2004.01.009","article-title":"Lymphocytes as a neural probe: Potential for studying psychiatric disorders","volume":"28","author":"Gladkevich","year":"2004","journal-title":"Prog. Neuro-Psychopharmacology Biol. Psychiatry."},{"key":"10.1016\/j.bbi.2022.03.016_b0160","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/mp.2009.81","article-title":"Increased levels of circulating insulin-related peptides in first-onset, antipsychotic na\u00efve schizophrenia patients","volume":"15","author":"Guest","year":"2010","journal-title":"Mol. Psychiatry."},{"key":"10.1016\/j.bbi.2022.03.016_b0165","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.psyneuen.2010.12.018","article-title":"Altered levels of circulating insulin and other neuroendocrine hormones associated with the onset of schizophrenia","volume":"36","author":"Guest","year":"2011","journal-title":"Psychoneuroendocrinology."},{"key":"10.1016\/j.bbi.2022.03.016_b0170","doi-asserted-by":"crossref","first-page":"T1","DOI":"10.1530\/JOE-13-0584","article-title":"Insulin signaling, resistance, and metabolic syndrome: Insights from mouse models into disease mechanisms","volume":"220","author":"Guo","year":"2014","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.bbi.2022.03.016_b0175","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.devcel.2005.12.002","article-title":"Dose-dependent interaction of Tbx1 and Crkl and locally aberrant RA signaling in a model of del22q11 syndrome","volume":"10","author":"Guris","year":"2006","journal-title":"Dev. Cell."},{"key":"10.1016\/j.bbi.2022.03.016_b0180","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.tem.2010.09.003","article-title":"Akt isoforms and glucose homeostasis - the leptin connection","volume":"22","author":"Hay","year":"2011","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.bbi.2022.03.016_b0185","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1038\/mp.2010.71","article-title":"Impaired glycolytic response in peripheral blood mononuclear cells of first-onset antipsychotic-naive schizophrenia patients","volume":"16","author":"Herberth","year":"2011","journal-title":"Mol. Psychiatry."},{"key":"10.1016\/j.bbi.2022.03.016_b0190","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.schres.2014.01.034","article-title":"Transcriptional consequences of schizophrenia candidate miR-137 manipulation in human neural progenitor cells","volume":"153","author":"Hill","year":"2014","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.bbi.2022.03.016_b0195","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/0306-9877(94)90020-5","article-title":"Schizophrenia is a diabetic brain state: An elucidation of impaired neurometabolism","volume":"43","author":"Holden","year":"1994","journal-title":"Med. Hypotheses."},{"key":"10.1016\/j.bbi.2022.03.016_b0200","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1000529","article-title":"A Flexible and accurate genotype imputation method for the next generation of genome-wide association studies","volume":"5","author":"Howie","year":"2009","journal-title":"PLoS Genet."},{"key":"10.1016\/j.bbi.2022.03.016_b0205","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.biopsych.2004.07.023","article-title":"Association of AKT1 with schizophrenia confirmed in a Japanese population","volume":"56","author":"Ikeda","year":"2004","journal-title":"Biol. Psychiatry."},{"key":"10.1016\/j.bbi.2022.03.016_b0210","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.neuron.2012.04.009","article-title":"De novo gene disruptions in children on the autistic spectrum","volume":"74","author":"Iossifov","year":"2012","journal-title":"Neuron."},{"key":"10.1016\/j.bbi.2022.03.016_b0215","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1186\/s12864-015-1511-7","article-title":"NF-\u03baB and IRF pathways: cross-regulation on target genes promoter level","volume":"16","author":"Iwanaszko","year":"2015","journal-title":"BMC Genomics."},{"key":"10.1016\/j.bbi.2022.03.016_b0220","doi-asserted-by":"crossref","first-page":"28066","DOI":"10.1074\/jbc.M805545200","article-title":"Leptin stimulates both JAK2-dependent and JAK2-independent signaling pathways","volume":"283","author":"Jiang","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbi.2022.03.016_b0225","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.2174\/1389450110607011421","article-title":"Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions","volume":"7","author":"Jope","year":"2006","journal-title":"Curr. Drug Targets."},{"issue":"1","key":"10.1016\/j.bbi.2022.03.016_b0230","article-title":"Schizophrenia","volume":"1","author":"Kahn","year":"2015","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.bbi.2022.03.016_b0235","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/273060","article-title":"Minimizing cardiovascular adverse effects of atypical antipsychotic drugs in patients with schizophrenia","volume":"2014","author":"Khasawneh","year":"2014","journal-title":"Cardiol. Res. Pract."},{"key":"10.1016\/j.bbi.2022.03.016_b0240","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jpsychires.2015.04.023","article-title":"Advanced glycation end products and schizophrenia: A systematic review","volume":"66\u201367","author":"Kouidrat","year":"2015","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.bbi.2022.03.016_b0245","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/sj.npp.1300027","article-title":"H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs","volume":"28","author":"Kroeze","year":"2003","journal-title":"Neuropsychopharmacology."},{"key":"10.1016\/j.bbi.2022.03.016_b0250","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/nchembio.2007.59","article-title":"High-content single-cell drug screening with phosphospecific flow cytometry","volume":"4","author":"Krutzik","year":"2008","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bbi.2022.03.016_b0255","article-title":"High-resolution copy number variation analysis of schizophrenia in Japan","volume":"1\u201311","author":"Kushima","year":"2016","journal-title":"Mol. Psychiatry"},{"issue":"1","key":"10.1016\/j.bbi.2022.03.016_b0260","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1021\/acschemneuro.8b00205","article-title":"Clinical trials and therapeutic rationale for drug repurposing in schizophrenia","volume":"10","author":"Lago","year":"2019","journal-title":"ACS Chem. Neurosci."},{"issue":"1","key":"10.1016\/j.bbi.2022.03.016_b0275","doi-asserted-by":"crossref","DOI":"10.1038\/s41398-021-01243-8","article-title":"Functional patient-derived cellular models for neuropsychiatric drug discovery","volume":"11","author":"Lago","year":"2021","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.bbi.2022.03.016_b0270","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1038\/s41380-018-0123-4","article-title":"Exploring the neuropsychiatric spectrum using high-content functional analysis of single-cell signaling networks","volume":"25","author":"Lago","year":"2020","journal-title":"Mol. Psychiatry."},{"key":"10.1016\/j.bbi.2022.03.016_b0280","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.bbi.2020.07.043","article-title":"Exploring cellular markers of metabolic syndrome in peripheral blood mononuclear cells across the neuropsychiatric spectrum","volume":"91","author":"Lago","year":"2021","journal-title":"Brain. Behav. Immun."},{"key":"10.1016\/j.bbi.2022.03.016_b0265","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aau9093","article-title":"Drug discovery for psychiatric disorders using high-content single-cell screening of signaling network responses ex vivo","volume":"5","author":"Lago","year":"2019","journal-title":"Sci. Adv."},{"issue":"1","key":"10.1016\/j.bbi.2022.03.016_b0285","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1093\/bmb\/ldv017","article-title":"Antipsychotic medication in schizophrenia: a review","volume":"114","author":"Lally","year":"2015","journal-title":"Br. Med. Bull."},{"key":"10.1016\/j.bbi.2022.03.016_b0290","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1192\/bjp.187.4.366","article-title":"Clinical implications of Brief Psychiatric Rating Scale scores","volume":"187","author":"Leucht","year":"2005","journal-title":"Br. J. Psychiatry."},{"key":"10.1016\/j.bbi.2022.03.016_b0295","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: A multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet."},{"key":"10.1016\/j.bbi.2022.03.016_b0300","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.cell.2015.05.047","article-title":"Data-Driven Phenotypic Dissection of AML Reveals Progenitor-like Cells that Correlate with Prognosis","volume":"162","author":"Levine","year":"2015","journal-title":"Cell."},{"key":"10.1016\/j.bbi.2022.03.016_b0305","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1038\/npp.2010.105","article-title":"Is glycogen synthase kinase-3 a central modulator in mood regulation?","volume":"35","author":"Li","year":"2010","journal-title":"Neuropsychopharmacology."},{"key":"10.1016\/j.bbi.2022.03.016_b0310","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.pnpbp.2013.01.004","article-title":"Association study between genes in Reelin signaling pathway and autism identifies DAB1 as a susceptibility gene in a Chinese Han population","volume":"44","author":"Li","year":"2013","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry."},{"key":"10.1016\/j.bbi.2022.03.016_b0315","article-title":"CD40 signaling induces type I interferon and immune control in mouse pancreatic cancer lacking the CXCL12-coat","volume":"204","author":"Li","year":"2020","journal-title":"J. Immunol."},{"key":"10.1016\/j.bbi.2022.03.016_b0320","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S0140-6736(09)60072-6","article-title":"Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study","volume":"373","author":"Lichtenstein","year":"2009","journal-title":"Lancet."},{"key":"10.1016\/j.bbi.2022.03.016_b0325","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.bbi.2012.09.011","article-title":"Peripubertal viral-like challenge and social isolation mediate overlapping but distinct effects on behaviour and brain interferon regulatory factor 7 expression in the adult Wistar rat","volume":"27","author":"Lukasz","year":"2013","journal-title":"Brain. Behav. Immun."},{"key":"10.1016\/j.bbi.2022.03.016_b0330","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1093\/schbul\/sbu045","article-title":"Systematic prioritization and integrative analysis of copy number variations in schizophrenia reveal key schizophrenia susceptibility genes","volume":"40","author":"Luo","year":"2014","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.bbi.2022.03.016_b0335","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1749-6632.2011.06216.x","article-title":"Advancing drug discovery for schizophrenia","volume":"1236","author":"Marder","year":"2011","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.bbi.2022.03.016_b0340","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/nature15526","article-title":"Differential responses to lithium in hyperexcitable neurons from patients with bipolar disorder","volume":"527","author":"Mertens","year":"2015","journal-title":"Nature."},{"key":"10.1016\/j.bbi.2022.03.016_b0345","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1600-0447.2008.01317.x","article-title":"The metabolic syndrome and schizophrenia","volume":"119","author":"Meyer","year":"2009","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.bbi.2022.03.016_b0350","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/nrd4088","article-title":"Therapeutic modulators of STAT signalling for human diseases","volume":"12","author":"Miklossy","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"issue":"7","key":"10.1016\/j.bbi.2022.03.016_b0355","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/nrd.2016.28","article-title":"Altering the course of schizophrenia: progress and perspectives","volume":"15","author":"Millan","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bbi.2022.03.016_b0360","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.biopsych.2011.04.013","article-title":"Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects","volume":"70","author":"Miller","year":"2011","journal-title":"Biol. Psychiatry."},{"issue":"1","key":"10.1016\/j.bbi.2022.03.016_b0365","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/npp.2011.181","article-title":"From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment","volume":"37","author":"Moghaddam","year":"2012","journal-title":"Neuropsychopharmacology."},{"key":"10.1016\/j.bbi.2022.03.016_b0370","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.pharmthera.2009.06.001","article-title":"Antipsychotic drug actions on gene modulation and signaling mechanisms","volume":"124","author":"Molteni","year":"2009","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bbi.2022.03.016_b0375","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.devcel.2005.12.003","article-title":"Crkl deficiency disrupts Fgf8 signaling in a mouse model of 22q11 deletion syndromes","volume":"10","author":"Moon","year":"2006","journal-title":"Dev. Cell."},{"key":"10.1016\/j.bbi.2022.03.016_b0380","doi-asserted-by":"crossref","first-page":"ra5","DOI":"10.1126\/scisignal.aab0467","article-title":"Allosteric signaling through an mGlu2 and 5-HT2A heteromeric receptor complex and its potential contribution to schizophrenia","volume":"9","author":"Moreno","year":"2016","journal-title":"Sci. Signal."},{"key":"10.1016\/j.bbi.2022.03.016_b0385","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/gene.2011.21","article-title":"IRF7: Activation, regulation, modification and function","volume":"12","author":"Ning","year":"2011","journal-title":"Genes Immun."},{"issue":"10039","key":"10.1016\/j.bbi.2022.03.016_b0390","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/S0140-6736(15)01121-6","article-title":"Schizophrenia","volume":"388","author":"Owen","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.bbi.2022.03.016_b0395","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1038\/npp.2011.24","article-title":"AKT kinase activity is required for lithium to modulate mood-related behaviors in mice","volume":"36","author":"Pan","year":"2011","journal-title":"Neuropsychopharmacology."},{"key":"10.1016\/j.bbi.2022.03.016_b0400","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/bdi.12228","article-title":"Region-specific dysregulation of glycogen synthase kinase-3\u03b2 and \u03b2-catenin in the postmortem brains of subjects with bipolar disorder and schizophrenia","volume":"17","author":"Pandey","year":"2015","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.bbi.2022.03.016_b0405","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1001\/jamapsychiatry.2016.3803","article-title":"Impaired Glucose Homeostasis in First-Episode Schizophrenia:\u202f: A systematic review and meta-analysis.","volume":"74","author":"Pillinger","year":"2017","journal-title":"JAMA Psychiatry."},{"key":"10.1016\/j.bbi.2022.03.016_b0415","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.biopsych.2007.09.024","article-title":"Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review","volume":"63","author":"Potvin","year":"2008","journal-title":"Biol. Psychiatry."},{"key":"10.1016\/j.bbi.2022.03.016_b0420","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nature12975","article-title":"A polygenic burden of rare disruptive mutations in schizophrenia","volume":"506","author":"Purcell","year":"2014","journal-title":"Nature."},{"key":"10.1016\/j.bbi.2022.03.016_b0425","unstructured":"R Core Team, R: A Language and Environment for Statistical Computing (2017)."},{"key":"10.1016\/j.bbi.2022.03.016_b0430","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1001\/2013.jamapsychiatry.4","article-title":"A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression","volume":"70","author":"Raison","year":"2013","journal-title":"JAMA Psychiatry."},{"key":"10.1016\/j.bbi.2022.03.016_b0435","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/nature13595","article-title":"Biological insights from 108 schizophrenia-associated genetic loci","volume":"511","author":"Ripke","year":"2014","journal-title":"Nature."},{"key":"10.1016\/j.bbi.2022.03.016_b0440","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nrd1346","article-title":"Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia","volume":"3","author":"Roth","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bbi.2022.03.016_b0445","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/j.1600-0854.2011.01178.x","article-title":"Mapping Insulin\/GLUT4 Circuitry","volume":"12","author":"Rowland","year":"2011","journal-title":"Traffic."},{"key":"10.1016\/j.bbi.2022.03.016_b0450","doi-asserted-by":"crossref","first-page":"22878","DOI":"10.1074\/jbc.271.37.22878","article-title":"Characterization of \u03b2-R1, a gene that is selectively induced by interferon \u03b2 (IFN-\u03b2) compared with IFN-\u03b1","volume":"271","author":"Sandhya Rani","year":"1996","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbi.2022.03.016_b0455","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/nrd.2016.230","article-title":"A comprehensive map of molecular drug targets","volume":"16","author":"Santos","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bbi.2022.03.016_b0460","doi-asserted-by":"crossref","first-page":"78","DOI":"10.9758\/cpn.2012.10.2.78","article-title":"Treatment response in first-episode schizophrenia","volume":"10","author":"Schennach","year":"2012","journal-title":"Clin. Psychopharmacol. Neurosci."},{"key":"10.1016\/j.bbi.2022.03.016_b0465","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.schres.2014.12.001","article-title":"Defining therapeutic benefit for people with schizophrenia: focus on negative symptoms","volume":"162","author":"Schooler","year":"2015","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.bbi.2022.03.016_b0470","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.biopsych.2005.05.005","article-title":"Further evidence for association of variants in the AKT1 gene with schizophrenia in a sample of European sib-pair families","volume":"58","author":"Schwab","year":"2005","journal-title":"Biol. Psychiatry."},{"key":"10.1016\/j.bbi.2022.03.016_b0475","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1093\/schbul\/sbt105","article-title":"Identification of subgroups of schizophrenia patients with changes in either immune or growth factor and hormonal pathways","volume":"40","author":"Schwarz","year":"2014","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.bbi.2022.03.016_b0480","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.137289","article-title":"RAGE impairs murine diabetic atherosclerosis regression and implicates IRF7 in macrophage inflammation and cholesterol metabolism","volume":"5","author":"Senatus","year":"2020","journal-title":"JCI Insight."},{"key":"10.1016\/j.bbi.2022.03.016_b0485","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/s41582-020-0364-0","article-title":"The polygenic architecture of schizophrenia \u2014 rethinking pathogenesis and nosology","volume":"16","author":"Smeland","year":"2020","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.bbi.2022.03.016_b0490","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/jcp.22022","article-title":"The activation of liver X receptors inhibits toll-like receptor-9-induced foam cell formation","volume":"223","author":"Sorrentino","year":"2010","journal-title":"J. Cell. Physiol."},{"issue":"5","key":"10.1016\/j.bbi.2022.03.016_b0495","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/s41588-019-0397-8","article-title":"Genome-wide association study identifies 30 loci associated with bipolar disorder","volume":"51","author":"Stahl","year":"2019","journal-title":"Nat Genet"},{"key":"10.1016\/j.bbi.2022.03.016_b0500","first-page":"2200","article-title":"Genetic variation in AKT1 is linked to dopamine-associated prefrontal cortical structure and function in humans","volume":"118","author":"Tan","year":"2008","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bbi.2022.03.016_b0505","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.biopsych.2007.06.005","article-title":"AKT1 is associated with schizophrenia across multiple symptom dimensions in the Irish study of high density schizophrenia families","volume":"63","author":"Thiselton","year":"2008","journal-title":"Biol. Psychiatry."},{"issue":"S2","key":"10.1016\/j.bbi.2022.03.016_b0510","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s00406-012-0354-3","article-title":"Blood test for schizophrenia","volume":"262","author":"Tomasik","year":"2012","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.bbi.2022.03.016_b0515","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.bbi.2015.10.019","article-title":"Pretreatment levels of the fatty acid handling proteins H-FABP and CD36 predict response to olanzapine in recent-onset schizophrenia patients","volume":"52","author":"Tomasik","year":"2016","journal-title":"Brain. Behav. Immun."},{"key":"10.1016\/j.bbi.2022.03.016_b0520","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.schres.2018.02.012","article-title":"Virus discovery analyses on post-mortem brain tissue and cerebrospinal fluid of schizophrenia patients","volume":"197","author":"Tomasik","year":"2018","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.bbi.2022.03.016_b0525","doi-asserted-by":"crossref","DOI":"10.1001\/jamapsychiatry.2019.0304","article-title":"Association of insulin resistance with schizophrenia polygenic risk score and response to antipsychotic treatment","volume":"76","author":"Tomasik","year":"2019","journal-title":"JAMA Psychiatry."},{"key":"10.1016\/j.bbi.2022.03.016_b0530","doi-asserted-by":"crossref","DOI":"10.1093\/schizbullopen\/sgaa044","article-title":"Leptin Serum Levels are Associated With GLP-1 Receptor Agonist-Mediated Effects on Glucose Metabolism in Clozapine- or Olanzapine-Treated, Prediabetic, Schizophrenia Patients","volume":"1","author":"Tomasik","year":"2020","journal-title":"Schizophr. Bull. Open."},{"key":"10.1016\/j.bbi.2022.03.016_b0535","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2014.52","article-title":"Evidence for disturbed insulin and growth hormone signaling as potential risk factors in the development of schizophrenia","volume":"4","author":"van Beveren","year":"2014","journal-title":"Transl. Psychiatry."},{"key":"10.1016\/j.bbi.2022.03.016_b0540","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.bbi.2017.10.003","article-title":"Evidence of microglial activation following exposure to serum from first-onset drug-na\u00efve schizophrenia patients","volume":"67","author":"van Rees","year":"2018","journal-title":"Brain. Behav. Immun."},{"key":"10.1016\/j.bbi.2022.03.016_b0545","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1017\/S0033291713002778","article-title":"Metabolic syndrome and metabolic abnormalities in patients with major depressive disorder: a meta-analysis of prevalences and moderating variables","volume":"44","author":"Vancampfort","year":"2014","journal-title":"Psychol. Med."},{"key":"10.1016\/j.bbi.2022.03.016_b0550","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/wps.20252","article-title":"Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis","volume":"14","author":"Vancampfort","year":"2015","journal-title":"World Psychiatry."},{"key":"10.1016\/j.bbi.2022.03.016_b0555","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/sj.npp.1301142","article-title":"Atypical antipsychotic drugs directly impair insulin action in adipocytes: effects on glucose transport, lipogenesis, and antilipolysis","volume":"32","author":"Vestri","year":"2007","journal-title":"Neuropsychopharmacology."},{"key":"10.1016\/j.bbi.2022.03.016_b0560","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","author":"World Medical Association","year":"2013","journal-title":"Jama."},{"key":"10.1016\/j.bbi.2022.03.016_b0565","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1111\/jcpp.12295","article-title":"Research Review: Polygenic methods and their application to psychiatric traits","volume":"55","author":"Wray","year":"2014","journal-title":"J. Child Psychol. Psychiatry."},{"key":"10.1016\/j.bbi.2022.03.016_b0570","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.4088\/JCP.v68n0906","article-title":"Association of AKT1 gene polymorphisms with risk of schizophrenia and with response to antipsychotics in the Chinese population","volume":"68","author":"Xu","year":"2007","journal-title":"J. Clin. Psychiatry."},{"key":"10.1016\/j.bbi.2022.03.016_b0575","doi-asserted-by":"crossref","unstructured":"S. Yang, R. Garner, L. Song, C. A. Miller, A. Polter, J. D. Sweatt, L. Mcmahon, A. A. Bartolucci, X. Li, R. S. Jope, Deficiency in the Inhibitory Serine-Phosphorylation of Glycogen Synthase Kinase-3 Increases Sensitivity to Mood Disturbances. 3, 1761\u20131774 (2010).","DOI":"10.1038\/npp.2010.43"},{"key":"10.1016\/j.bbi.2022.03.016_b0580","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jbior.2015.11.003","article-title":"Primary phospholipase C and brain disorders","volume":"61","author":"Yang","year":"2016","journal-title":"Adv. Biol. Regul."},{"key":"10.1016\/j.bbi.2022.03.016_b0585","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1038\/mp.2016.261","article-title":"Forebrain-specific ablation of phospholipase C\u03b31 causes manic-like behavior","volume":"22","author":"Yang","year":"2017","journal-title":"Mol. Psychiatry."},{"key":"10.1016\/j.bbi.2022.03.016_b0590","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1128\/CMR.8.1.131","article-title":"Viruses, schizophrenia, and bipolar disorder","volume":"8","author":"Yolken","year":"1995","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.bbi.2022.03.016_b0595","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2006.02.009","article-title":"Insulin receptor deficits in schizophrenia and in cellular and animal models of insulin receptor dysfunction","volume":"84","author":"Zhao","year":"2006","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.bbi.2022.03.016_b0600","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jpsychires.2017.04.004","article-title":"Adjunctive celecoxib for schizophrenia: a meta-analysis of randomized, double-blind, placebo-controlled trials","volume":"92","author":"Zheng","year":"2017","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.bbi.2022.03.016_b0605","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.euroneuro.2017.06.011","article-title":"How well do patients with a first episode of schizophrenia respond to antipsychotics: A systematic review and meta-analysis","volume":"27","author":"Zhu","year":"2017","journal-title":"Eur. Neuropsychopharmacol."}],"container-title":["Brain, Behavior, and Immunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889159122000848?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889159122000848?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T08:15:52Z","timestamp":1760170552000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889159122000848"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":120,"alternative-id":["S0889159122000848"],"URL":"https:\/\/doi.org\/10.1016\/j.bbi.2022.03.016","relation":{},"ISSN":["0889-1591"],"issn-type":[{"type":"print","value":"0889-1591"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Peripheral lymphocyte signaling pathway deficiencies predict treatment response in first-onset drug-na\u00efve schizophrenia","name":"articletitle","label":"Article Title"},{"value":"Brain, Behavior, and Immunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbi.2022.03.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}